{
    "clinical_study": {
        "@rank": "140",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04345276"
        },
        "id_info": {
            "org_study_id": "ASC-CTP-HS-01",
            "nct_id": "NCT04345276"
        },
        "brief_title": "Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection",
        "official_title": "An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Huoshenshan Hospital",
                "agency_class": "Other"
            },
            "collaborator": {
                "agency": "Ascletis Pharmaceuticals Co., Ltd.",
                "agency_class": "Industry"
            }
        },
        "source": "Huoshenshan Hospital",
        "oversight_info": {
            "has_dmc": "No",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Evaluation of the efficacy and safety of Danoprevir sodium tablet combined with ritonavir for\n      SARS-CoV-2 infected patients."
        },
        "detailed_description": {
            "textblock": "Given no specific antiviral therapies for COVID-19 approved yet and Danoprevir sodium tablet,\n      an oral Hepatitis C virus protease inhibitor, approved in China in June 2018 , this open,\n      controlled trial will evaluate the efficacy and safety of Danoprevir sodium tablet in\n      hospitalized patients infected with SARS-CoV-2."
        },
        "overall_status": "Recruiting",
        "start_date": {
            "@type": "Actual",
            "#text": "March 18, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "May 31, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "April 30, 2020"
        },
        "phase": "Phase 4",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "intervention_model": "Single Group Assignment",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Rate of composite adverse outcomes",
            "time_frame": "Within 10 days after administration",
            "description": "Defined as SPO2\u2264 93% without oxygen supplementation, PaO2/FiO2 \u2264 300mmHg or a respiratory rate \u226530 breaths per min without supplemental oxygen min without supplemental oxygen"
        },
        "secondary_outcome": [
            {
                "measure": "Time to recovery",
                "time_frame": "Within 10 days after administration",
                "description": "Clinical recovery was defined as sustained (48 hours) alleviation of illness based on symptom scores (fever, cough, diarrhea, myalgia, dyspnea) all being absent and no evidence for progression (newly-presented dyspnea, SpO2 decline \u22653%, respiratory rate \u2265 30 breaths per min without supplemental oxygen)."
            },
            {
                "measure": "Rate of no fever",
                "time_frame": "Within 10 days after administration"
            },
            {
                "measure": "Rate of no cough",
                "time_frame": "Within 10 days after administration"
            },
            {
                "measure": "Rate of no dyspnea",
                "time_frame": "Within 10 days after administration"
            },
            {
                "measure": "Rate of no requiring supplemental oxygen",
                "time_frame": "Within 10 days after administration"
            },
            {
                "measure": "Rate of undetectable New coronavirus pathogen nucleic acid",
                "time_frame": "Within 10 days after administration"
            },
            {
                "measure": "Rate of mechanical ventilation",
                "time_frame": "Within 10 days after administration"
            },
            {
                "measure": "Rate of ICU admission",
                "time_frame": "Within 10 days after administration"
            },
            {
                "measure": "Rate of serious adverse event",
                "time_frame": "Within 10 days after administration"
            }
        ],
        "number_of_arms": "1",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "40"
        },
        "condition": "COVID-19",
        "arm_group": {
            "arm_group_label": "Danoprevir+Ritonavir group",
            "arm_group_type": "Experimental"
        },
        "intervention": {
            "intervention_type": "Drug",
            "intervention_name": "Danoprevir+Ritonavir",
            "description": "Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.",
            "arm_group_label": "Danoprevir+Ritonavir group",
            "other_name": "Ganovo"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged 18-75 years old;\n\n          2. Pneumonia patients with SARS-CoV-2 infection were confirmed to be positive by RT-PCR\n             and clinical manifestations. The diagnosis standard refers to the diagnosis and\n             treatment plan for pneumonia with SARS-CoV-2 infection (Current Trial Version);\n\n          3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized\n             (the diagnosis time of respiratory system discomfort shall not exceed 7 days);\n\n          4. Women and their partners who have no planned pregnancy for nearly half a year and are\n             willing to take effective contraceptive measures within 30 days from the first\n             administration of the study drug to the last administration;\n\n          5. Agree not to participate in other clinical research within 30 days from the first\n             administration of the study drug to the last administration;\n\n          6. Patients who voluntarily sign informed consent.\n\n        Exclusion Criteria:\n\n          1. The pneumonia patients with severe SARS-CoV-2 infection met one of the following\n             conditions: respiratory distress, RR\u226530 times / min; or SaO2 / SpO2\u226493% in resting\n             state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2)\n             \u2264300MMHG (1mmhg = 0.133kpa);\n\n          2. Pneumonia patients with severe SARS-CoV-2 infection meet one of the following\n             conditions: respiratory failure and need mechanical ventilation; or shock; or other\n             organ failure combined with ICU monitoring treatment;\n\n          3. Severe liver disease (such as child Pugh score \u2265C, AST > 5 times upper limit);\n\n          4. Patients with contraindications specified in the instructions of danoprevir and\n             ritonavir tablets;\n\n          5. Patients who plan to take protease inhibitors other than danoprevir and ritonavir\n             simultaneously during the trial.\n\n          6. The pregnancy test of female subjects in the screening period was positive;\n\n          7. The researchers judged that it was not suitable to participate in this clinical trial\n             (for example, patients who may be transferred to another hospital during the study\n             period; patients with multiple basic diseases, etc.)."
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "75 Years",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Yahong Chen, MD",
            "role": "Study Director",
            "affiliation": "Ascletis Pharmaceuticals Co., Ltd."
        },
        "overall_contact": {
            "last_name": "Junxue Wang, MD",
            "phone": "8618917387623",
            "email": "docd1@sina.com"
        },
        "overall_contact_backup": {
            "last_name": "Bo Wei, MD",
            "phone": "8615921231996",
            "email": "weibo0816@163.com"
        },
        "location": {
            "facility": {
                "name": "Huoshenshan Hostipal",
                "address": {
                    "city": "Wuhan",
                    "state": "Hubei",
                    "zip": "430104",
                    "country": "China"
                }
            },
            "status": "Recruiting",
            "contact": {
                "last_name": "Junxue Wang, MD",
                "phone": "8618917387623",
                "email": "docd1@sina.com"
            },
            "contact_backup": {
                "last_name": "Bo Wei, MD",
                "phone": "8615921231996",
                "email": "weibo0816@163.co"
            }
        },
        "location_countries": {
            "country": "China"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "April 10, 2020",
        "study_first_submitted_qc": "April 10, 2020",
        "study_first_posted": {
            "@type": "Estimate",
            "#text": "April 14, 2020"
        },
        "last_update_submitted": "April 10, 2020",
        "last_update_submitted_qc": "April 10, 2020",
        "last_update_posted": {
            "@type": "Estimate",
            "#text": "April 14, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "condition_browse": {
            "mesh_term": "Infection"
        },
        "intervention_browse": {
            "mesh_term": [
                "Ritonavir",
                "Lactams"
            ]
        },
        "patient_data": {
            "sharing_ipd": "Undecided"
        }
    }
}